{
    "organizations": [],
    "uuid": "5e50513e82458567accf18be55922d910ab0548e",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/25/globe-newswire-insys-therapeutics-to-report-first-quarter-2018-results-on-may-8.html",
    "ord_in_thread": 0,
    "title": "INSYS Therapeutics to Report First Quarter 2018 Results on May 8",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "PHOENIX, April 25, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its first quarter 2018 financial results on Tuesday, May 8, after the U.S. financial markets close.\nFollowing the release, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 5:00 p.m. Eastern Daylight Time to discuss the results.\nInterested parties can listen to the call live as it occurs via the company’s website, https://www.insysrx.com/ , on the Investors section’s Presentations & Events page; or by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.), and using the Conference ID 6338979. A webcasted replay of the call will be available on the site a few hours after the event.\nAbout INSYS\nINSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.\nCONTACT: Corporate Communications Investor Relations Joe McGrath Jackie Marcus or Chris Hodges INSYS Therapeutics Alpha IR Group 480-500-3101 312-445-2870 jmcgrath@insysrx.com INSY@alpha-ir.com\nSource:Insys Therapeutics, Inc.",
    "published": "2018-04-25T14:00:00.000+03:00",
    "crawled": "2018-04-25T14:21:02.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "phoenix",
        "april",
        "globe",
        "newswire",
        "insys",
        "therapeutic",
        "nasdaq",
        "insy",
        "leader",
        "development",
        "manufacture",
        "commercialization",
        "pharmaceutical",
        "cannabinoids",
        "spray",
        "technology",
        "today",
        "announced",
        "release",
        "first",
        "quarter",
        "financial",
        "result",
        "tuesday",
        "may",
        "financial",
        "market",
        "close",
        "following",
        "release",
        "saeed",
        "motahari",
        "president",
        "chief",
        "executive",
        "officer",
        "andrew",
        "long",
        "chief",
        "financial",
        "officer",
        "host",
        "conference",
        "call",
        "eastern",
        "daylight",
        "time",
        "discus",
        "result",
        "interested",
        "party",
        "listen",
        "call",
        "live",
        "occurs",
        "via",
        "company",
        "website",
        "http",
        "investor",
        "section",
        "presentation",
        "event",
        "page",
        "dialing",
        "inside",
        "outside",
        "using",
        "conference",
        "id",
        "webcasted",
        "replay",
        "call",
        "available",
        "site",
        "hour",
        "event",
        "insys",
        "insys",
        "therapeutic",
        "specialty",
        "pharmaceutical",
        "company",
        "develops",
        "commercializes",
        "innovative",
        "drug",
        "novel",
        "drug",
        "delivery",
        "system",
        "therapeutic",
        "molecule",
        "improve",
        "patient",
        "quality",
        "life",
        "using",
        "proprietary",
        "spray",
        "technology",
        "capability",
        "develop",
        "pharmaceutical",
        "cannabinoids",
        "insys",
        "developing",
        "pipeline",
        "product",
        "intended",
        "address",
        "unmet",
        "medical",
        "need",
        "clinical",
        "shortcoming",
        "existing",
        "commercial",
        "product",
        "insys",
        "committed",
        "developing",
        "medication",
        "potentially",
        "treating",
        "addiction",
        "opioids",
        "opioid",
        "overdose",
        "epilepsy",
        "disease",
        "area",
        "significant",
        "unmet",
        "need",
        "contact",
        "corporate",
        "communication",
        "investor",
        "relation",
        "joe",
        "mcgrath",
        "jackie",
        "marcus",
        "chris",
        "hodges",
        "insys",
        "therapeutic",
        "alpha",
        "ir",
        "group",
        "jmcgrath",
        "insy",
        "source",
        "insys",
        "therapeutic",
        "inc"
    ]
}